NCT06111768View on ClinicalTrials.gov

Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Cardiorenal Syndrome
Interventions
DRUG

Dapagliflozin

Receipt of 10mg oral dose of dapagliflozin once daily for three days

Trial Locations (1)

06520

RECRUITING

Yale New Haven Hospital, New Haven

All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

Yale University

OTHER